| Testicular cancer survivorship: research strategies and recommendations. | |
| | |
MedLine Citation:
|
PMID: 20585105 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems. Data on underlying genetic or molecular factors that might identify those patients at highest risk for late sequelae are sparse. Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies. We review research priorities identified during an international workshop devoted to testicular cancer survivors. Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions. Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer. |
| | |
Authors:
|
Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa |
Related Documents
:
|
22658275 - Application of molecular techniques in the diagnosis, prognosis and management of patie... 22819905 - Thymidylate synthase and cyclin d1 protein expression in lymph node negative colorectal... 6177295 - Gynecomastia after cytotoxic therapy for metastatic testicular cancer. 22326975 - Line-1 methylation in the peripheral blood mononuclear cells of cancer patients. 23471665 - Bladder polypoid cystitis-derived a20 associates with tumorigenesis. 20335045 - Difficulties in decision making regarding chemotherapy for older cancer patients: a cen... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review Date: 2010-06-28 |
Journal Detail:
|
Title: Journal of the National Cancer Institute Volume: 102 ISSN: 1460-2105 ISO Abbreviation: J. Natl. Cancer Inst. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-04 Completed Date: 2010-08-25 Revised Date: 2011-08-25 |
Medline Journal Info:
|
Nlm Unique ID: 7503089 Medline TA: J Natl Cancer Inst Country: United States |
Other Details:
|
Languages: eng Pagination: 1114-30 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. lois_travis@urmc.rochester.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / administration & dosage*, adverse effects* Antineoplastic Combined Chemotherapy Protocols / administration & dosage, adverse effects Cardiovascular Diseases / chemically induced, genetics Clinical Trials as Topic Cognition / drug effects Employment Evidence-Based Medicine Fatigue / chemically induced Genetic Predisposition to Disease Genome-Wide Association Study Humans Infertility, Male / chemically induced, genetics Male Models, Statistical Neoplasm Recurrence, Local / prevention & control Neoplasms, Second Primary / prevention & control Paresthesia / chemically induced, genetics Platinum Compounds / administration & dosage, adverse effects Population Surveillance Pulmonary Fibrosis / chemically induced, genetics Quality of Life Renal Insufficiency / chemically induced, genetics Risk Assessment Survival Rate Survivors / statistics & numerical data* Testicular Neoplasms / drug therapy*, mortality, psychology Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
5U56CA118635/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Platinum Compounds |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expert holistic nurses' advice to nursing students.
Next Document: Effect of Modest Salt Reduction on Skin Capillary Rarefaction in White, Black, and Asian Individuals...